Information:
Fel:
Nyckelord
Nevrologi ×
- Clinical Trial (61)
- Adverse event (61)
- Parkinsons Disease (20)
- Restless Legs Syndrome (17)
- Concomitant Medication (13)
- Parkinson Disease (7)
- Migraine Disorders (5)
- Multiple System Atrophy (4)
- Telephone (3)
- Sumatriptan (2)
- Dopamine Agonists (2)
- Eligibility Determination (2)
- Epilepsy (2)
- Alzheimer Disease (2)
- Laboratories (2)
- Memory Disorders (2)
- Naproxen (2)
- Pharmacogenetics (1)
- Respiration (1)
- Seizures (1)
- Therapeutics (1)
- Drugs, Investigational (1)
- Stroke (1)
- Endpoint Determination (1)
- Cardiology (1)
- Ischemic Attack, Transient (1)
- Vital Signs (1)
- Checklist (1)
- End of Study (1)
- Diagnostic Procedure (1)
- Electrocardiogram (ECG) (1)
- Coronary Disease (1)
- Drug Therapy (1)
- Liver (1)
Innehållsförteckning
Valda datamodeller
Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.
61 Sökresultat.
Item-grupper: Date of visit, Assessment Date, Adverse Event; Concomitant Agent; Evaluation, Repeat, Liver, Adverse Event, Non-serious Adverse Event, Serious Adverse Event, Concomitant Agent, Laboratory Procedures, Vital signs, Pharmacokinetic aspect, Blood, Repeat, Pulmonary function tests, Repeat, Holter Electrocardiography, Repeat, Holter Electrocardiography, Abnormality, Repeat, Telemetry, Repeat, Telemetry, Abnormality, Repeat, 12 lead ECG, Abnormality, Repeat, 12 lead ECG
Item-grupper: administrative data, adverse events
Item-grupper: administrative data, adverse events, adverse events
Item-grupper: time of documentation, patient information, adverse event, study drug, patient information, principal investigator
Item-grupper: Administrative, Any Adverse Events?, Any Adverse Events?, Any Adverse Events?, Any Adverse Events? (Follow-up), Adverse Event , Adverse Event, Adverse Event - Investigator’s Signature, Serious Adverse Event, Serious Adverse Event - Relevant Laboratory Data, Serious Adverse Event - Investigator's Signature
Item-grupper: Administrative, Concomitant Medication, Concomitant Medication , Adverse Event, Adverse Event , Advrese Event - Investigator’s Signature, Serious Adverse Event, Serious Adverse Event - Relevant Laboratory Data, Serious Adverse Event - Investigator's Signature
Item-grupper: Administrative, Adverse Event (Day 1), Adverse Event (Day 2 - 43; Extra Clinic Visit 1 - 3), Adverse Event (PK Visit), Adverse Event (Last Clinic Visit)
Item-grupper: Administrative, Adverse Events, Adverse Event - Intensity Changes, Serious Adverse Event, Randomisation, Adverse Event - Seriousness, Relevant Concomitant/Treatment Medications, Lab Sequence Number, Relevant Diagnostic Results, Adverse Events - Rechallenge, General Narrative Comments, Possible suicidality-related adverse event - Section 1, Possible suicidality-related adverse event - Section 2, Possible suicidality-related adverse event - Section 3 , Possible suicidality-related adverse event - Section 4 , Possible suicidality-related adverse event - Section 5 , Possible suicidality-related adverse event - Section 6 , Possible suicidality-related adverse event - Section 7 , Possible suicidality-related adverse event - Section 8
Item-grupper: Date of visit, Adverse Event, Liver, Experimental drug, Liver, Pharmacokinetic aspects, Liver, Liver, Adverse Event, Disease, Liver, Adverse Event, Disease, Drug-related disorder, Liver, Adverse Event, Liver diseases, Other, Liver, Adverse Event, Disease, Other, Liver, Adverse Event, Alcohol consumption, Liver, Adverse Event, Imaging of liver, Liver, Adverse Event, Biopsy of liver
Item-grupp: Adverse Events; Concomitant Medications
Item-grupper: Administrative, Investigational Product, Status of Treatment Blind, Consent for Pharmacogenetic Research, PGx - Blood Sample Collection (DNA), PGx - Withdrawal of Consent, PGx - Blood Sample Destruction, Concomitant Medications, Concomitant Medications , Non-Serious Adverse Events, Non-Serious Adverse Events , Serious Adverse Events, Serious Adverse Events - Section 1, Serious Adverse Events - Section 2 (Seriousness), Serious Adverse Events - Section 3 (Demography Data), Serious Adverse Events - Section 4, Serious Adverse Events - Section 5 (Possible Cause of SAE), Serious Adverse Events - Medical Conditions, Serious Adverse Events - Section 7 (Other relevant Risk Factors), Serious Adverse Events - Section 8 (Relevant Concomitant Medication), Serious Adverse Events - Section 9 (Details of Investigational Product(s)), Serious Adverse Events - Section 10 ( Details of relevant Assessments), Serious Adverse Events - Section 11 (Narrative Remarks), Serious Adverse Events - Investigator's signature
Item-grupper: Administrative , Haematology , Clinical Chemistry , Plasma Concentrations of AEDs , Adverse Experiences and Concomitant Medication, Admission Criteria, Randomisation, Compliance Record, Adverse Experiences, Adverse Experiences, Concomitant AED Medication, Concomitant AED Medication , Emergency AED Therapy used irregularly as required, Emergency AED Therapy used irregularly as required, Concomitant Medication other than AEDs, Concomitant Medication other than AEDs , Seizure Record, Atypical Absence Seizures (1 Hour Count)